<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262808</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000448633</org_study_id>
    <secondary_id>URCC-U1203</secondary_id>
    <secondary_id>URCC-RSRB-09956</secondary_id>
    <secondary_id>BRLX-001-0837</secondary_id>
    <secondary_id>DUMC-7135-05-5R0</secondary_id>
    <nct_id>NCT00262808</nct_id>
  </id_info>
  <brief_title>GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer</brief_title>
  <official_title>A PHASE II Study of GM-CSF As Pre- And Post-operative Adjuvant Therapy For Stage II And III Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <brief_summary>
    <textblock>
      RATIONALE: Colony-stimulating factors, such as GM-CSF, may increase the number of immune&#xD;
      cells found in bone marrow or peripheral blood and may help the immune system recover from&#xD;
      the side effects of chemotherapy or kill tumor cells. Drugs used in chemotherapy, such as&#xD;
      fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy&#xD;
      after surgery may kill any remaining tumor cells. Sometimes, after surgery, the tumor may not&#xD;
      need additional treatment until it progresses. In this case, observation may be sufficient.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well GM-CSF and combination chemotherapy work in&#xD;
      treating patients who are undergoing surgery for stage II or stage III colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of neoadjuvant and adjuvant sargramostim (GM-CSF) and adjuvant&#xD;
           chemotherapy in patients with resectable stage II or III colon cancer.&#xD;
&#xD;
        -  Determine the efficacy, in terms of enhanced tumor-associated macrophage response, of&#xD;
           this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine overall survival and time to progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Neoadjuvant therapy and surgery: Patients receive sargramostim (GM-CSF) subcutaneously&#xD;
           (SC) once daily beginning between days -16 and -12 and continuing until day -1. Patients&#xD;
           undergo surgical resection on day 0. Patients with stage I or IV disease are removed&#xD;
           from the study. All other patients proceed to adjuvant chemotherapy or observation.&#xD;
&#xD;
        -  Adjuvant chemotherapy or observation: Patients with high-risk stage II or any stage III&#xD;
           disease are assigned to group 1 or 2. Patients with low-risk stage II disease are&#xD;
           assigned to group 3.&#xD;
&#xD;
             -  Group 1 (adjuvant therapy for high-risk stage II disease): Patients receive&#xD;
                leucovorin calcium IV over 2 hours and fluorouracil IV on days 1, 8, 15, 22, 29 and&#xD;
                36. Patients also receive GM-CSF SC once daily on days 50-54. Treatment repeats&#xD;
                every 56 days for up to 4 courses in the absence of disease progression or&#xD;
                unacceptable toxicity.&#xD;
&#xD;
             -  Group 2 (adjuvant therapy for stage III disease): Patients receive adjuvant&#xD;
                chemotherapy and GM-CSF as in group 1. Alternatively, patients may receive&#xD;
                oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and&#xD;
                fluorouracil IV over 46 hours beginning on day 1. These patients also receive&#xD;
                GM-CSF SC once daily on days 10-14 of every fourth course. Treatment repeats every&#xD;
                14 days for up to 12 courses in the absence of disease progression or unacceptable&#xD;
                toxicity.&#xD;
&#xD;
             -  Group 3 (low-risk stage II disease): Patients undergo observation only every 3&#xD;
                months.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a change in tumor-associated macrophage VEGF expression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free and overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon&#xD;
&#xD;
               -  Stage II or III disease&#xD;
&#xD;
               -  No carcinoma in situ&#xD;
&#xD;
               -  No perforated or obstructed tumors&#xD;
&#xD;
               -  No dual primary lesions by colonoscopy or barium enema&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
               -  Distal and proximal bowel end must be &gt; 5 cm from tumor&#xD;
&#xD;
               -  Tumor must not extend below peritoneal reflection&#xD;
&#xD;
          -  No distant intra-abdominal metastases (even if resected)&#xD;
&#xD;
          -  No rectal cancer&#xD;
&#xD;
               -  No tumors that require opening of the pelvic peritoneum to define the extent of&#xD;
                  disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No allergy to yeast or yeast-based products&#xD;
&#xD;
          -  No allergy to sargramostim (GM-CSF)&#xD;
&#xD;
          -  No allergy to fluorouracil&#xD;
&#xD;
          -  No allergy to leucovorin calcium&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of Crohn's disease&#xD;
&#xD;
          -  No history of ulcerative colitis&#xD;
&#xD;
          -  No other malignancy within the past 3 years except superficial squamous cell or basal&#xD;
             cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy, including fluorouracil, for colon cancer&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for colon cancer&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other prior therapy for colon cancer&#xD;
&#xD;
          -  No concurrent immunosuppressant therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alok A. Khorana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

